ECE2011 Poster Presentations Diabetes therapy (26 abstracts)
Introduction: By using insulin analogue, it is expected to improve glycemic regulation in poorly controlled type 2 diabetes (t2DM). The aim of the study was to examine the quality of glycemic control and quality of life (QoL) of patients managed with insulin analogues, previously treated with human insulin.
Materials and methods: The pilot study included 30 t2DM outpatients, divided into two groups (15 subjects) the first group was treated with human insulin, while the second group was managed with insulin analogues during at least one year, but previously treated with human insulin. The following parameters were observed: sex, age, occupation, t2DM and insulin use duration, examinees estimation of insulin therapy effects, GHQ12 score, and HbA1c levels. Obtained data were analyzed by SPSS 17.0.
Results: The mean t2DM duration and duration of insulin therapy management was 5.5±3.5 and 3.5±3 years respectively. Twenty (66.6%) subjects assessed overall effects of insulin therapy as grades 3/4 of 5. The mean HbA1c levels were 9.1 and 7.2% respectively (t=4.869, P<0.01). HbA1c levels and subjective grades of insulin effects negatively correlated (ρ=−0.568, P<0.01). GHQ12 score was 9±3.5 and did not statistically differ between groups (Z=−1.481, P>0.05). GHQ12 score and subjective grades of insulin-analogue effects negatively correlated (ρ=−0.730; P<0.01).
Conclusion: Insulin analogue improves glycemic control of t2DM patients. The subjective assessment of the insulin therapy effects correlated with the objective QoL parameter GHQ12 score.